Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
06 Febbraio 2023 - 2:15PM
Business Wire
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical
stage oncology company today announced the promotion of David
Gaiero to Chief Financial Officer (CFO). David was previously Vice
President of Finance at Cyteir. As CFO, David will continue to
manage the finance department, to oversee the company’s overall
financial operations, and to help drive the long-term business and
financial strategy of Cyteir, reporting directly to the President
& CEO.
“When Dave joined Cyteir in 2020, he brought a wealth of
experience that helped us internalize the finance function, prepare
for our IPO, and operate as a public company. His strong financial
foundation and disciplined approach to resource management will be
critical as we advance CYT-0851,” said Markus Renschler, MD,
President and Chief Executive Officer of Cyteir. “I congratulate
Dave on his well-deserved promotion and look forward to his
contributions on the management team.”
David joined Cyteir in December of 2020 as Vice President of
Finance. Prior to joining Cyteir, he served as Interim Chief
Financial Officer of Wave Life Sciences, where he joined as Vice
President, Corporate Controller in 2017. Prior to joining Wave,
from 2015 to 2017, David served as Vice President, Global
Controller of OvaScience, Inc. and from 2007 to 2015 he held
various positions of increasing responsibility and scope in finance
and accounting at iRobot Corporation. He began his career in public
accounting at PricewaterhouseCoopers LLP. David received a B.B.A.
in Accounting from the University of Massachusetts, Amherst, and is
a Certified Public Accountant in Massachusetts.
“I am honored to take on the role of CFO at Cyteir as we
continue to advance CYT-0851 in ovarian cancer,” said David Gaiero.
“I look forward to stewarding Cyteir’s resources and leading its
financial strategy to support the company’s mission.”
About Cyteir Therapeutics, Inc.
Cyteir is a clinical-stage oncology company that is focused on
the development of CYT-0851, an oral investigational drug that
inhibits monocarboxylate transporters. Cyteir’s current priority in
CYT-0851 development is in combination with capecitabine and
gemcitabine in a Phase 1/2 clinical study, including patients with
advanced ovarian cancer. Follow Cyteir on social media: LinkedIn
and Twitter and at www.cyteir.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230206005229/en/
Cyteir Investor Relations 857-285-4140 ir@cyteir.com
Grafico Azioni Cyteir Therapeutics (NASDAQ:CYT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Cyteir Therapeutics (NASDAQ:CYT)
Storico
Da Giu 2023 a Giu 2024